{"id":"W3216996692","doi":"10.1093/neuonc/noab196.233","title":"CTNI-08. DB102-01 ENGAGE STUDY: A BIOMARKER-GUIDED, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER PHASE 3 CLINICAL TRIAL OF DB102 IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)","year":2021,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Temozolomide; Placebo; Internal medicine; Biomarker; Clinical endpoint; Oncology; Surrogate endpoint; Clinical trial; Phases of clinical research; Progression-free survival; Randomized controlled trial; Radiation therapy; Chemotherapy; Pathology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002598598,0.0006775719,0.004423124,0.0006017472,0.00011855,0.00004273823,0.0002718947,0.0004800232,0.0002432693],"category_scores_gemma":[0.003805907,0.0004866328,0.000934529,0.0007491886,0.0003809065,0.0001318075,0.0002333884,0.0008665217,0.00006040389],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002867287,"about_ca_system_score_gemma":0.0009880472,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001299092,"about_ca_topic_score_gemma":0.0007483978,"domain_scores_codex":[0.9901058,0.004160491,0.002897803,0.001278879,0.0008025852,0.0007544179],"domain_scores_gemma":[0.9899603,0.006956441,0.001057843,0.001003369,0.0005145203,0.0005075356],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7767483,0.1249828,0.08225557,0.00003376573,0.001497865,0.005533672,0.000437985,0.00001045956,0.000461539,0.000007986137,0.001006796,0.007023239],"study_design_scores_gemma":[0.9614909,0.02817339,0.004069105,0.0001076709,0.001600668,0.00006158838,0.0003903446,0.0003059934,0.0008994371,0.000002724224,0.00256365,0.0003345084],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9789061,0.0001831965,0.00003286875,0.001084871,0.001680158,0.01737496,0.00005472645,0.00007511582,0.000608005],"genre_scores_gemma":[0.994861,0.0001245425,0.0004492939,0.0008928638,0.0002774325,0.003149312,0.0001204758,0.00009805911,0.00002699211],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1847426,"threshold_uncertainty_score":0.9997585,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0727596786582985,"score_gpt":0.3900084116739805,"score_spread":0.317248733015682,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}